Burrard Pharmaceuticals Enterprises Ltd., Vancouver, Canada, supports importers, distributors, and local marketing-authorisation holders seeking doxycycline finished-dose supply through a partner-site model.
Email bd@burrardpharma.com with your company, territory, and finished-dose supply, dossier support, or both.
Burrard does not manufacture in-house. Manufacture for this programme is placed with a qualified partner GMP site named under CDA.
Site GMP evidence is shared in the quality pack under CDA. Site GMP is not product approval.
This page discusses the INN doxycycline. Vibramycin is named for identification only and is not a Burrard trademark or a Burrard-branded good.
Doxycycline is a tetracycline-class antibacterial in the established oral class.
Oral solid, strengths confirmed under CDA.
The salt or hydrate, for example hyclate or monohydrate, is not chosen on this page. Other tetracyclines, liquids, and combinations are out of scope unless separately confirmed under CDA.
If the registration names a hydrate, write it as the presentation to be checked. Burrard has not accepted it by drafting this page. Company, territory, and finished-dose supply, dossier support, or both are the rest of the email.
Scope table. Public copy only. Strengths, packs, stability, and dossier status are confirmed under CDA, not on this page.
| INN | Doxycycline |
| Dosage form | Oral solid, strengths confirmed under CDA |
| Strengths | Confirmed under CDA / quality pack |
| Pack sizes | Confirmed under CDA / quality pack |
| Stability / climate zone | Not stated. Confirmed under CDA. |
| Dossier format | Not asserted. Confirmed under CDA if a file is offered. |
| Facility class | Named site, in the quality pack. |
| WHO prequalification | Not claimed |
| Bioequivalence | Not claimed |
| MOQ / Incoterms | Confirmed under CDA |
| Exclusivity note | Long off-patent generic. Salt or hydrate is confirmed under CDA, not on this page. |
Burrard coordinates doxycycline finished-dose supply for commercial partners. Manufacture is at a qualified partner GMP site named under CDA, not at a Burrard plant. The reader is a partner, not a patient. This page is not a dose and not a superiority claim. Price and pack count are not published. The order of work is the quality pack, then site and batch evidence under CDA, then a short supply call.
The pack is a B2B qualification file. It is not a marketing authorisation and not a patient leaflet.
GMP or API documents describe the named site or the API. They are not Burrard product approval in the United States, the European Union, Canada, or elsewhere. This page claims no FDA, EMA, or Health Canada product approval and no country-of-origin marketing authorisation. The local MAH or importer holds the destination authorisation.
Doxycycline is a long off-patent generic. Hyclate and monohydrate have both been commercial oral solids for many years. This page does not pick one. The salt or hydrate is confirmed under CDA. Later patents on particular modified-release products are not cleared here, and those products are out of scope unless named under CDA.
Burrard discusses supply only where relevant exclusivity has ended. Vibramycin is an originator name for identification only, not a Burrard trademark.
Burrard does not quote a molecule under a live patent or exclusivity dispute in the requested territory. Supply is discussed only where relevant exclusivity has ended.
Each link is a separate finished-dose programme with its own exclusivity note. Azithromycin · Ciprofloxacin · Cephalexin · Amoxicillin.
No. Burrard does not manufacture in-house. Manufacture is placed with a qualified partner GMP site named under CDA. The site is named in the quality pack after CDA.
No. This page does not claim FDA, EMA, or Health Canada product approval for doxycycline. The local MAH or importer holds destination marketing authorisation. Site GMP evidence is not product approval.
Oral solid, strengths confirmed under CDA. Pack size, stability zone, and CTD or ACTD status are not stated here.
No. The salt or hydrate is confirmed under CDA, not on this page. Doxycycline is a long off-patent generic. That does not clear every modified-release patent or every country. Other tetracyclines are out of scope. Supply is discussed only where relevant exclusivity has ended.
Email bd@burrardpharma.com with your company, territory, and whether you need finished-dose supply, dossier support, or both. The quality pack and a short supply call follow CDA.
Email bd@burrardpharma.com with company, territory, and finished-dose supply, dossier support, or both. You can also use the contact page.
For importers, distributors, and local marketing-authorisation holders only. Not patient information, not dosing guidance, and not an offer or a price. Burrard Pharmaceuticals Enterprises Ltd. does not manufacture in-house and does not claim FDA, EMA, or Health Canada product approval. Site GMP is not product approval. The local MAH or importer holds destination authorisation. Supply is discussed only where relevant exclusivity has ended. Strengths, packs, stability zones, and CTD status are confirmed under CDA, not here. Brand names are for identification only.